These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 35112760)
1. Epidemiological study of multiple sclerosis in the Illawarra region. Dal SR; Elphick TL; Fuller K Intern Med J; 2023 Jun; 53(6):1010-1017. PubMed ID: 35112760 [TBL] [Abstract][Full Text] [Related]
3. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study. Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609 [TBL] [Abstract][Full Text] [Related]
4. Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis. Hollingworth S; Walker K; Page A; Eadie M Mult Scler; 2013 Nov; 19(13):1712-6. PubMed ID: 23530000 [TBL] [Abstract][Full Text] [Related]
5. Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. Sloka JS; Pryse-Phillips WE; Stefanelli M Can J Neurol Sci; 2005 Feb; 32(1):37-42. PubMed ID: 15825544 [TBL] [Abstract][Full Text] [Related]
6. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study. Blinkenberg M; Kjellberg J; Ibsen R; Magyari M Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969 [TBL] [Abstract][Full Text] [Related]
7. Profile of Polish patients with primary progressive multiple sclerosis. Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082 [TBL] [Abstract][Full Text] [Related]
8. Epidemiological study of multiple sclerosis in La Rioja. Bártulos Iglesias M; Marzo Sola ME; Estrella Ruiz LA; Bravo Anguiano Y Neurologia; 2015; 30(9):552-60. PubMed ID: 24975346 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022. Simpson-Yap S; Maddox D; Reece J; Lechner-Scott J; Shaw C; Taylor B; Kalincik T; van der Walt A; Boggild M Mult Scler Relat Disord; 2023 Sep; 77():104845. PubMed ID: 37442078 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses. Sumelahti ML; Tienari PJ; Hakama M; Wikström J J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):25-8. PubMed ID: 12486261 [TBL] [Abstract][Full Text] [Related]
11. Impact of multiple sclerosis phenotypes on burden of disease in Finland. Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776 [No Abstract] [Full Text] [Related]
12. Multiple sclerosis in Finland 2018-Data from the national register. Laakso SM; Viitala M; Kuusisto H; Sarasoja T; Hartikainen P; Atula S; Tienari PJ; Soilu-Hänninen M Acta Neurol Scand; 2019 Nov; 140(5):303-311. PubMed ID: 31271648 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic inertia in relapsing-remitting multiple sclerosis. Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868 [TBL] [Abstract][Full Text] [Related]
14. Incidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study. O'Connell K; Tubridy N; Hutchinson M; McGuigan C Mult Scler Relat Disord; 2017 Apr; 13():75-80. PubMed ID: 28427707 [TBL] [Abstract][Full Text] [Related]
15. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878 [TBL] [Abstract][Full Text] [Related]
17. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis. Knowles LM; Tingey JL; Newman AK; von Geldern G; Alschuler KN Mult Scler Relat Disord; 2022 Jul; 63():103918. PubMed ID: 35700673 [TBL] [Abstract][Full Text] [Related]
18. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001 [TBL] [Abstract][Full Text] [Related]
19. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. McDonnell GV; Mawhinney H; Graham CA; Hawkins SA; Middleton D J Neurol Sci; 1999 May; 165(1):77-83. PubMed ID: 10426152 [TBL] [Abstract][Full Text] [Related]
20. Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors. Etemadifar M; Salari M; Esnaashari A; Ghazanfaripoor F; Sayahi F; Akhavan Sigari A; Sedaghat N Mult Scler Relat Disord; 2022 Feb; 58():103488. PubMed ID: 34999375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]